Sign in
Explore the registryTrack Nivolumab + relatlimab's trials

RELATIVITY-127

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Nivolumab + RelatlimabOngoingActive not recruitingPhase 3Open NCT05625399 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…